Cue Biopharma (CUE) Current Assets (2017 - 2025)
Cue Biopharma (CUE) posted Current Assets of $37.0 million for Q4 2025, up 43.24% sequentially from $25.8 million in Q3 2025, and up 47.12% YoY from $25.1 million in Q4 2024.
Cue Biopharma (CUE) Current Assets (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Current Assets for 9 years, with the latest figure at $37.0 million in Q4 2025.
- Quarterly Current Assets rose 47.12% year-over-year to $37.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.0 million (up 47.12% YoY) and the FY2025 annual result came in at $37.0 million, up 47.12% from the prior year.
- Current Assets advanced to $37.0 million in Q4 2025 per CUE's latest filing, from $25.8 million in the prior quarter.
- Over five years, Current Assets peaked at $79.7 million in Q2 2021 and troughed at $15.9 million in Q1 2025.
- A 5-year average of $53.4 million and a median of $59.2 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2021 and 2025: Current Assets jumped 51.21% in 2021, then sank 64.34% in 2025.
- Over 5 years, Current Assets stood at $68.5 million in 2021, then advanced by 12.73% to $77.2 million in 2022, then tumbled by 33.34% to $51.5 million in 2023, then slumped by 51.14% to $25.1 million in 2024, then surged by 47.12% to $37.0 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $37.0 million, $25.8 million, and $30.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 26.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.98 Mn |
| Sep 30, 2025 | 25.82 Mn |
| Jun 30, 2025 | 30.84 Mn |
| Mar 31, 2025 | 15.93 Mn |
| Dec 31, 2024 | 25.14 Mn |
| Sep 30, 2024 | 37.26 Mn |
| Jun 30, 2024 | 33.90 Mn |
| Mar 31, 2024 | 44.67 Mn |
| Dec 31, 2023 | 51.45 Mn |
| Sep 30, 2023 | 57.52 Mn |
| Jun 30, 2023 | 60.94 Mn |
| Mar 31, 2023 | 68.76 Mn |
| Dec 31, 2022 | 77.19 Mn |
| Sep 30, 2022 | 61.70 Mn |
| Jun 30, 2022 | 69.00 Mn |
| Mar 31, 2022 | 75.95 Mn |
| Dec 31, 2021 | 68.47 Mn |
| Sep 30, 2021 | 70.26 Mn |
| Jun 30, 2021 | 79.68 Mn |
| Mar 31, 2021 | 77.41 Mn |